IRIS
RENI, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 8.480
AS - Asia 8.446
NA - Nord America 5.633
SA - Sud America 2.586
AF - Africa 195
Continente sconosciuto - Info sul continente non disponibili 11
OC - Oceania 10
Totale 25.361
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.315
RU - Federazione Russa 5.290
SG - Singapore 2.961
CN - Cina 2.631
BR - Brasile 2.158
HK - Hong Kong 1.081
VN - Vietnam 966
SE - Svezia 841
IT - Italia 823
FR - Francia 448
DE - Germania 308
GB - Regno Unito 216
BD - Bangladesh 182
AR - Argentina 180
IN - India 161
CA - Canada 148
FI - Finlandia 148
MX - Messico 103
NL - Olanda 82
ZA - Sudafrica 81
EC - Ecuador 77
ID - Indonesia 73
PL - Polonia 72
IQ - Iraq 55
JP - Giappone 54
ES - Italia 44
TR - Turchia 44
AT - Austria 43
CO - Colombia 43
IE - Irlanda 43
PY - Paraguay 36
UA - Ucraina 31
PK - Pakistan 30
VE - Venezuela 30
CL - Cile 28
MA - Marocco 27
EG - Egitto 22
UZ - Uzbekistan 22
PE - Perù 18
KE - Kenya 16
AE - Emirati Arabi Uniti 15
JM - Giamaica 14
TN - Tunisia 14
LT - Lituania 13
SA - Arabia Saudita 13
AL - Albania 12
IL - Israele 12
PH - Filippine 12
AZ - Azerbaigian 11
MY - Malesia 11
CR - Costa Rica 10
DZ - Algeria 10
IR - Iran 10
JO - Giordania 10
KZ - Kazakistan 10
LB - Libano 10
NP - Nepal 10
TH - Thailandia 10
CZ - Repubblica Ceca 9
AU - Australia 8
BE - Belgio 8
KR - Corea 8
EU - Europa 7
HN - Honduras 7
OM - Oman 7
PS - Palestinian Territory 7
UY - Uruguay 7
BH - Bahrain 6
BO - Bolivia 6
CI - Costa d'Avorio 6
MD - Moldavia 6
RO - Romania 6
BB - Barbados 5
BY - Bielorussia 5
DO - Repubblica Dominicana 5
NI - Nicaragua 5
PA - Panama 5
PT - Portogallo 5
HU - Ungheria 4
NG - Nigeria 4
SV - El Salvador 4
TT - Trinidad e Tobago 4
XK - ???statistics.table.value.countryCode.XK??? 4
BG - Bulgaria 3
CH - Svizzera 3
CY - Cipro 3
KW - Kuwait 3
LV - Lettonia 3
QA - Qatar 3
SN - Senegal 3
YE - Yemen 3
AO - Angola 2
BA - Bosnia-Erzegovina 2
BN - Brunei Darussalam 2
BS - Bahamas 2
ET - Etiopia 2
GA - Gabon 2
GE - Georgia 2
GT - Guatemala 2
HR - Croazia 2
Totale 25.328
Salva come PNG Salva come JPEG
Città #
Moscow 1.284
Singapore 1.252
Dallas 1.237
Hong Kong 1.072
Ashburn 690
San Jose 576
Shanghai 475
Hefei 420
Lauterbourg 367
Ho Chi Minh City 363
Lawrence 342
Princeton 342
Beijing 269
New York 212
São Paulo 201
Hanoi 194
Milan 164
Los Angeles 117
Helsinki 100
Santa Clara 97
Boardman 84
Nuremberg 82
Rome 78
Munich 73
Rio de Janeiro 71
Orem 69
Warsaw 62
Johannesburg 46
Mexico City 46
Belo Horizonte 45
Montreal 45
London 44
Tokyo 43
Dublin 42
Haiphong 41
Guangzhou 39
Cesano Boscone 37
Chennai 37
Denver 37
Poplar 37
Chicago 36
Da Nang 35
Campinas 34
Stockholm 34
Turku 34
Brasília 32
Houston 32
Porto Alegre 32
Phoenix 31
Biên Hòa 28
Atlanta 27
Brooklyn 27
Manchester 27
Quito 27
Frankfurt am Main 26
The Dalles 26
Toronto 26
Amsterdam 25
Council Bluffs 24
Curitiba 24
Hangzhou 24
Seattle 24
Dhaka 23
Guayaquil 23
Tianjin 23
Buffalo 21
Tashkent 21
Washington 21
Guarulhos 20
Naples 20
Mumbai 19
Barnet 18
Brescia 18
Hải Dương 18
Shenzhen 18
Ankara 17
Asunción 17
Boston 17
San Francisco 17
Baghdad 16
Columbus 16
Goiânia 16
Vienna 16
Changsha 15
Osasco 15
Ribeirão Preto 15
Juiz de Fora 14
Lappeenranta 14
Thái Bình 14
Turin 14
Aracaju 13
Bogotá 13
Falkenstein 13
Montes Claros 13
Nairobi 13
Recife 13
Santiago 13
Sorocaba 13
Thái Nguyên 13
Verona 13
Totale 12.093
Salva come PNG Salva come JPEG
Nome #
Exploring machine learning tools in a retrospective case-study of patients with metastatic non-small cell lung cancer treated with first-line immunotherapy: A feasibility single-centre experience 197
Postoperative Outcomes and Functional Recovery After Preoperative Combination Chemotherapy for Pancreatic Cancer: A Propensity Score-Matched Study 166
A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma 154
A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen). 151
(Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial 151
Brain metastases in locally advanced nonsmall cell lung carcinoma after multimodality treatment - Risk factors analysis 149
Linee guida AIOM per le neoplasie cerebrali. 147
Endoscopic ultrasound-guided choledochoduodenostomy versus hepaticogastrostomy combined with gastroenterostomy in malignant double obstruction (CABRIOLET_Pro): A prospective comparative study 145
EUS-guided GastroEnterostomy for management of malignant Gastric Outlet Obstruction: a prospective cohort study with matched comparison with Enteral Stenting 144
A Comprehensive Characterization of Stemness in Cell Lines and Primary Cells of Pancreatic Ductal Adenocarcinoma 143
A multicenter study of treatment of primary CNS lymphoma 143
An integrated clinical pathway for pancreatic and periampullary tumor management within the Pancreas Unit network in Lombardy, Italy 142
Communication, understanding and engagement of patients with pancreatic cancer at time of diagnosis 141
A four-step method to centralize pancreatic surgery, accounting for volume, performance and access to care 134
Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial 130
A MULTICENTER TRIAL ASSESSING FEASIBILITY AND EFFICACY OF A COMBINATION OF HIGH-DOSE METHOTREXATE, CYTARABINE AND THIOTEPA IN PATIENTS WITH PRIMARY CNS LYMPHOMA: IMPACT ON OUTCOME OF CYTARABINE DOSE 129
A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer 128
A preoperative score to predict early death after pancreatic cancer resection 127
Chemotherapy in elderly patients with pancreatic cancer: Efficacy, feasibility and future perspectives 125
A pilot study of chlorambucil in pre-treated metastatic pancreatic adenocarcinoma patients bearing germline BRCA or other DNA damage repair system variants 119
Ex-vivo investigation of radiofrequency ablation in pancreatic adenocarcinoma after neoadjuvant chemotherapy 119
DIAGNOSTIC DELAY AT DIAGNOSIS AND TIME-TO-TREATMENT INFLUENCE OVERALL SURVIVAL OF PANCREATIC CANCER PATIENTS 118
A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile 118
A multicenter study of the prognosis and treatment of adult brain ependymal tumors 116
Exploring the optimal therapeutic management of stage ypIA pancreatic ductal adenocarcinoma patients in the era of primary chemotherapy 114
Diagnostic and therapeutic management of neuroendocrine lung tumors. A clinical study of 44 cases 114
A systematic review of surgical resection of liver-only synchronous metastases from pancreatic cancer in the era of multiagent chemotherapy 114
A randomized phase II trial of adjuvant chemotherapy with cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG regimen) or gemcitabine alone after curative resection for pancreatic cancer 112
ASO Visual Abstract: Very Early Recurrence After Curative Resection for Pancreatic Ductal Adenocarcinoma: Proof of Concept for a "Biologic R2 Definition" 112
ASO Visual Abstract: The Impact of CT-Assessed Liver Steatosis on Postoperative Complications After Pancreaticoduodenectomy for Cancer 110
A phase II trial of second-line therapy with trabectedin in metastatic pancreatic adenocarcinoma 110
Early intravenous administration of nutritional support (IVANS) in metastatic gastric cancer patients at nutritional risk, undergoing first-line chemotherapy: study protocol of a pragmatic, randomized, multicenter, clinical trial 109
A MULTICENTER RETROSPECTIVE STUDY OF CHEMOTHERAPY IN ADULTS WITH EPENDYMOMA. GICNO (GRUPPO ITALIANO COOPERATIVO NEURO-ONCOLOGIA) 108
Anatomically resectable versus biologically borderline resectable pancreatic cancer definition: refining the border beyond anatomical criteria and biological aggressiveness 105
A phase II trial of PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced gallbladder, biliary tract, and ampulla of Vater adenocarcinoma, preliminary results 105
A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients 105
COMMUNI.CARE (COMMUNIcation and Patient Engagement at Diagnosis of PAncreatic CAncer): Study Protocol 104
Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients 104
Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocarcinoma 103
A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-Oncologia 102
The Impact of CT-Assessed Liver Steatosis on Postoperative Complications After Pancreaticoduodenectomy for Cancer 101
Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma 101
Quaderni dell’infermiere-Neurologia III edizione 101
EUS-guided gallbladder drainage and subsequent peroral endoscopic cholecystolithotomy: A tool to reduce chemotherapy discontinuation in neoplastic patients? 100
Prediction of early distant recurrence in upfront resectable pancreatic adenocarcinoma: A multidisciplinary, machine learning-based approach 99
A RANDOMIZED PHASE II TRIAL OF TWO DIFFERENT FOUR DRUG COMBINATIONS IN ADVANCED PANCREATIC ADENOCARCINOMA: CISPLATIN, CAPECITABINE, GEMCITABINE PLUS EITHER EPIRUBICIN OR DOCETAXEL 99
Pathologic complete response following neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma: Impact on survival and recurrence 98
Corneal and Epidermal Nerve Quantification in Chemotherapy Induced Peripheral Neuropathy 98
The role of biliary events in treatment and survival of patients with advanced pancreatic ductal adenocarcinoma 97
3D conformal radiotherapy significantly reduces toxicity of post-prostatectomy adjuvant or salvage irradiation 97
Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies 96
Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey 95
Adjuvant Chemoradiation in Pancreatic Cancer: A Pooled Analysis in Elderly (≥75 years) Patients 95
ENDOSCOPIC ULTRASOUND-GUIDED HYBRID THERM ABLATION (EUS-HTP) IN PATIENTS (PTS) WITH LOCALLY ADVANCED (LA) PANCREATIC DUCTAL ADENOCARCINOMA (PDAC): A CASE-CONTROL COMPARATIVE SURVIVAL ANALYSIS 95
Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes 94
Cyclophosphamide maintenance to extend combination chemotherapy-free interval in metastatic pancreatic ductal adenocarcinoma 94
Efficacy of endoscopic ultrasound-guided ablation with the hybridtherm probe in locally advanced or borderline resectable pancreatic cancer: A phase ii randomized controlled trial 94
Landscape of Health-Related Quality of Life in Patients with Early-Stage Pancreatic Cancer Receiving Adjuvant or Neoadjuvant Chemotherapy: A Systematic Literature Review 93
Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial 93
Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer 93
Sex dimorphism and cancer immunotherapy: May pregnancy solve the puzzle? 92
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: Results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial 92
RNA Extraction from Endoscopic Ultrasound-Acquired Tissue of Pancreatic Cancer Is Feasible and Allows Investigation of Molecular Features 90
Isolated lung metastases from pancreatic ductal adenocarcinoma (PDAC): Diagnostic and therapeutic challenges of a different disease 89
An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study 89
Adjuvant chemotherapy in ductal adenocarcinoma of pancreas: a comparison among three regimens 89
Evolving pancreatic cancer treatment: From diagnosis to healthcare management 89
Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic ductal adenocarcinoma patients 89
Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey 88
Clinical signature and pathogenetic factors of diabetes associated with pancreas disease (T3cDM): a prospective observational study in surgical patients 87
Circulating Chromogranin A Is Cleaved Into Vasoregulatory Fragments in Patients With Pancreatic Ductal Adenocarcinoma 86
A retrospective analysis of postradiation chemotherapy in 133 patients with glioblastoma multiforme 86
Necrosis volume and Choi criteria predict the response to endoscopic ultrasonography-guided HybridTherm ablation of locally advanced pancreatic cancer 85
A retrospective series of upfront therapy in primary brain lymphomas 85
Prognosis of Upfront Surgery for Pancreatic Cancer: A Systematic Review and Meta-Analysis of Prospective Studies 85
Adjuvant PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) or Gemcitabine Followed by Chemoradiation in Pancreatic Cancer: A Randomized Phase II Trial 85
Clinical Relevance of the Dose of Cytarabine in the Upfront Treatment of Primary CNS Lymphomas with Methotrexate-Cytarabine Combination 84
Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas 84
Neoadjuvant chemoradiotherapy in patients with esopageal or esophageal gastric junction cancer 84
Survival analysis of the metastatic cohort of Italian Association of Medical Oncology (AIOM) GARIBALDI survey. 84
Survival analysis of the non-metastatic cohort of the Italian Association for Medical Oncology (AIOM) Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy (GARIBALDI) 83
Feasibility of therapeutic endoscopic ultrasound in the bridge-to-surgery scenario: The example of pancreatic adenocarcinoma 82
ASO Visual Abstract: Proposal for a New Pathologic Prognostic Index After Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma 82
Treatment sequences and prognostic/predictive factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a real-world study in Europe 81
Erratum: Time course of hypothalamic-pituitary deficiency in adults receiving cranial radiotherapy for primary extrasellar brain tumors (Radiotherapy and Oncology 99 (2011) (23-28)) 81
Routine Molecular Profiling in Both Resectable and Unresectable Pancreatic Adenocarcinoma: Relevance of Cytologic Samples 81
Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients 81
The impact of nutritional status on pancreatic cancer therapy 80
MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas 80
Proposal for a New Pathologic Prognostic Index After Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma (PINC). 80
Overall Survival With Adjuvant mFOLFIRINOX for Pancreatic Cancer 79
Brain metastases (BM) in locally advanced non-small cell lung cancer (LAD-NSCLC) after multimodality treatment (MMT): Risk factors analysis. 79
New era for pancreatic endoscopic ultrasound: From imaging to molecular pathology of pancreatic cancer 79
Lessons and open questions in borderline resectable pancreatic cancer 78
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial 78
Very Early Recurrence After Curative Resection for Pancreatic Ductal Adenocarcinoma: Proof of Concept for a “Biological R2 Definition” 78
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort 77
Nomogram for Estimating Overall Survival in Patients with Metastatic Pancreatic Cancer 75
REDISCOVER guidelines for borderline-resectable and locally advanced pancreatic cancer: management algorithm, unanswered questions, and future perspectives 75
Gene expression analysis of embryonic pancreas development master regulators and terminal cell fate markers in resected pancreatic cancer: A correlation with clinical outcome 74
Totale 10.325
Salva come PNG Salva come JPEG
Categoria #
all - tutte 162.116
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 162.116
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022329 0 0 0 30 10 2 5 232 18 5 8 19
2022/20231.774 786 437 54 14 13 220 50 92 51 17 23 17
2023/2024871 53 52 88 93 84 132 26 86 23 35 56 143
2024/20255.355 652 118 88 131 165 457 635 453 971 827 397 461
2025/202617.487 1.181 1.384 1.790 2.521 1.239 414 1.370 1.259 4.841 912 563 13
Totale 25.879